Kura Oncology amends executive severance agreements for CEO, CCO, and COO

Kura Oncology, Inc.

CEO Wilson: 12 months base salary (non-CIC) or 24 months base + 200% bonus (CIC), full equity acceleration.
CCO Powl and COO Ford: 12 months base (non-CIC) or 18 months base + 150% bonus (CIC), full equity acceleration.
All executives get COBRA premium continuation (12 months non-CIC, 18-24 months CIC) and option exercise extension to 12 months.
Amendments effective July 24-27, 2026; other terms unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.